Skip to main content
SpringerLink
Log in

The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Iodine-131 metaiodobenzylguanidine (131I-MIBG), a radiopharmaceutical agent used for scintigraphic localization of pheochromocytomas, has been employed to treat malignant pheochromocytomas since 1983 in a few specialized centers around the world. We review our clinical experience together with the published experience of 23 other centers in 10 countries, regarding the use of 131I-MIBG for treating patients with malignant adrenal pheochromocytomas or extra-adrenal paragangliomas. There were a total of 116 evaluable patients: 3 were from our current report and another 113 were reported in the literature from 1983 to 1996. A majority of the patients were selected for treatment based upon positive tracer uptake studies. The cumulative dose of 131I-MIBG administered ranged from 96 to 2,322 mCi (3.6 to 85.9 GBq), with a mean (±SD) of 490±350 mCi (18.1 ±13.0 GBq). The subjects received a mean single therapy dose of 158 mCi (5.8 GBq) and the number of doses administered ranged from 1 to 11, with a mean of 3.3±2.2 doses. Initial symptomatic improvement was achieved in 76% of patients, tumor responses in 30%, and hormonal responses in 45%. Five patients had complete tumor and hormonal responses, ranging from 16 to 58 months, which were sustained at the time of reporting. Patients with metastases to soft tissue had more favorable responses to treatment than those with metastases to bone. No difference was noted in the age between the responders and non-responders. Adverse effects, recorded in 41 % of the treated patients, were generally mild except for one fatality from bone marrow aplasia. Among 89 patients with follow-up data, 45% of the responders had relapsed with recurrent or progressive disease after a mean interval of 29.3±31.1 months (median 19 months). Of patients with an initial response to 131I-MIBG, death was reported in 33% after a mean of 23.2±8.1 months (median 22 months) following treatment. Of non-responders, death was reported in 45% after a mean of 14.3±8.3 months (median 13 months). In conclusion, this review suggests that 131I-MIBG therapy may be a useful palliative adjunct in selected patients with malignant pheochromocytoma or paraganglioma. Although controlled studies are lacking, our review raises the hope that this therapeutic modality may prolong survival with an occasional sustained complete remission or possible cure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Heerden J.A., Sheps S.G., Hamberger B., Sheedy P.F., Poston J.G., Remine W.H. Pheochromocytoma: current status and changing trends. Surgery. 91: 367, 1982.

    PubMed  Google Scholar 

  2. Mahoney E.M., Harrison J.H. Malignant pheochromocytoma: clinical course and treatment. J.Urol. 118: 225, 1977.

    PubMed  CAS  Google Scholar 

  3. Drasin H. Treatment of malignant pheochromocytoma. West. J. Med. 128: 106, 1978.

    PubMed Central  PubMed  CAS  Google Scholar 

  4. Robinson R.G., DeQuattro V., Grushkin C.M., Lieberman E. Childhood pheochromocytoma: treatment with alpha methyltyrosine for resistant hypertension. J. Pediatr. 91: 143, 1977.

    Article  PubMed  CAS  Google Scholar 

  5. Scott H.W., Reynolds V., Green N., Page D., Oates J.A., Robertson D., Roberts S. Clinical experience with malignant pheochromocytoma. Surg. Gyneco. I Obstet. 154: 801, 1982.

    Google Scholar 

  6. Keiser H.R., Goldstein D.S., Wade J.L., Douglas F.L., Averbuch S.D. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 7(Suppl I): 1–18, 1985.

    Google Scholar 

  7. Lewi H.J.E., Reid R., Mucci B., Davidson J.K., Kyle K.F., MacPherson S.G., Semple P., Kaye S. Malignant phaeochromocytoma. Br. J. Urol. 57: 394, 1985.

    Article  PubMed  CAS  Google Scholar 

  8. Averbuch S.D., Steakley C.S., Young R.C., Gelmann E.P., Goldstein D.S., Stull R., Keiser H.R. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann. Intern. Med. 109: 267, 1988.

    Article  PubMed  CAS  Google Scholar 

  9. Sisson J.C., Frager M.S., Valk T.W., Gross M.D., Swanson D.P., Wieland D.M., Tobes M.C., Beierwaltes W.H., Thompson N.W. Scintigraphic localization of pheochromocytoma. N. Engl.J. Med. 305: 12, 1981.

    Article  PubMed  CAS  Google Scholar 

  10. Sisson J., Shapiro B., Beierwaltes W.H., Nakajo M., Glowniak J., Mangner T., Carey J.E., Swanson D.P., Copp J., Satterlee W., Wieland D. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans. Assoc. Am. Physicians. 96: 209, 1983.

    PubMed  CAS  Google Scholar 

  11. Sisson J.C., Shapiro B., Beierwaltes W.H., Glowniak J.V., Nakajo M., Mangner T.J., Carey J.E., Swanson D.P., Copp J.E., Satterlee W.G., Wieland D.M. Radiopharmaceutical treatment of malignant pheochromocytoma. J. Nucl. Med. 24: 197, 1984.

    Google Scholar 

  12. Sisson J.C., Wieland D.M. Radiolabelled meta-iodobenzylguanidine: pharmacology and clinical studies. Am. J. Physiol. Imaging 1: 96, 1986.

    PubMed  CAS  Google Scholar 

  13. Thompson N.M., Allo M.D., Shapiro B., Sisson J.C., Beierwaltes W. Extra-adrenal and metastatic pheochromocytoma: the role of 131I meta-iodobenzylguanidine in localization and management. World J.Surg. 8: 605; 1984.

    Article  PubMed  CAS  Google Scholar 

  14. Shapiro B., Sisson J.C., Eyre P., Copp J.E., Dmuchowski C., Beierwaltes W.H. 131I-MIBG — a new agent in diagnosis and treatment of pheochromocytoma. Cardiology. 72(Suppl I): 137, 1985.

    Article  PubMed  Google Scholar 

  15. Khafagi F.A., Shapiro B., Fischer M., Sisson J.C., Hutchinson R., Beierwaltes W.H. Pheochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. Eur. J. Nuc. Med. 18: 191, 1991.

    Article  CAS  Google Scholar 

  16. Krempf M., Lumbroso J., Mornex R., Brendel A.J., Wemeau J.L., Delisle M.J., Aubert B., Carpentier P., Fleury-Goyon M.C., Gibold C., Guyot M., Lahneche B., Marchandise X., Schlumberger M., Charbonnel B., Chatal J.F. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J. Clin. Endocrinol. Metab. 72: 455, 1991.

    Article  PubMed  CAS  Google Scholar 

  17. Krempf M., Lumbroso J., Mornex R., Brendel A.J., Wemeau J.L., Delisle M.J., Aubert B., Carpentier P., Fleury-Goyon M.C., Gibold C., Guyot M., Lahneche B., Marchandise X., Schlumberger M., Charbonnel B., Chatal J.F. Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicenter study. J. Nucl. Biol. Med. 35: 284, 1991.

    PubMed  CAS  Google Scholar 

  18. Mornex R., Badet C., Peyrin L. Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990. J. Endocrinol. Invest. 15: 643, 1992.

    Article  PubMed  CAS  Google Scholar 

  19. Brendel A.J., Jeandot R., Guyot M., Lambert B., Drouillard J. Radionuclide therapy of pheochromocytomas and neuroblastomas using iodine-131 metaiodobenzylguanidine (MIBG). Clin. Nucl. Med. 14: 19, 1989.

    Article  PubMed  CAS  Google Scholar 

  20. Schlumberger M., Gicquel C., Lumbroso J., Tenenbaum F., Comoy E., Bosq J., Fonseca E., Ghillani P.P., Aubert B., Travagli J.P., Gardet P., Parmentier C. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J. Endocrinol. Invest. 15: 631, 1992.

    Article  PubMed  CAS  Google Scholar 

  21. Schvartz C., Gibold C., Vuillemin B., Delisle M.J. Results of [131I]metaiodobenzylguanidine therapy administered to three patients with malignant pheochromocytoma. J. Nucl. Biol. Med. 35: 305, 1991.

    PubMed  CAS  Google Scholar 

  22. Pujol P., Bringer J., Faurous P., Jaffiol C. Metastatic pheochromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy. Eur. J. Nucl. Med. 22: 382, 1995.

    Article  PubMed  CAS  Google Scholar 

  23. Fisher M. Therapy of pheochromocytoma with [131 I]metaiodobenzylguanidine. J. Nucl. Biol. Med. 35: 292, 1991.

    Google Scholar 

  24. Vetter H., Fischer M., Muller-Rensing R., Vetter W., Winterberg B. [131I]-meta-iodobenzylguanidine in treatment of malignant pheochromocytomas. Lancet. 2: 107, 1983.

    Article  PubMed  CAS  Google Scholar 

  25. Lewington V.J., Zivanovic M.A., Tristam M., McEwan A.J.B., Ackery D.M. Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. J. Nucl. Biol. Med. 35: 280, 1991.

    PubMed  CAS  Google Scholar 

  26. Bomanji J., Britton K.E., Ur E., Hawkins L., Grossman A.B., Besser G.M. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine. Nucl. Med. Commun. 14: 856, 1993.

    Article  PubMed  CAS  Google Scholar 

  27. Bestagno M., Pizzocaro C., Maira G., Terzi A., Panarotto M.B., Guerra P. Results of [131I]metaiodobenzylguanidine treatment in metastatic malignant phaeochromocytoma. J. Nucl. Biol. Med. 35: 277, 1991.

    PubMed  CAS  Google Scholar 

  28. Trocone L., Rufini V., Montemaggi P., Danza F.M., Lasorella A., Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine. Eur. J. Nucl. Med. 16: 325, 1990.

    Article  Google Scholar 

  29. Trocone L., Rufini V., Daidone M.S., De Santis M., Luzi S. [131I]metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group. J. Nucl. Biol. Med. 35: 295, 1991.

    Google Scholar 

  30. Colombo L., Lomuscio G., Vignati A., Dottorini M.E. Preliminary results of [131I]metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma. J. Nucl. Biol. Med. 35: 300, 1991.

    PubMed  CAS  Google Scholar 

  31. Limone P., Pogliano G., Castellano G., Argiro G., Isaia G.C., Favero A., Cottino F., Rizzi G., Molinatti G.M. 131-I-meta-iodobenzylguanidine for the diagnosis and treatment of pheochromocytoma. Panminerva Med. 30: 169, 1988.

    PubMed  CAS  Google Scholar 

  32. Hoefnagel C.A., Voute P.A., de Kraker J., Marcuse H.R. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J.Nucl. Med. 28: 308, 1987.

    PubMed  CAS  Google Scholar 

  33. Voute P.A., Hoefnagel C.A., de Kraker J., Evans A.E., Hayes A., Green A. Radionuclide therapy of neural crest tumors. Med. Pediatr. Oncol. 15: 192, 1987.

    Article  PubMed  CAS  Google Scholar 

  34. Konings J.E., Bruning P.F., Abeling N.G.G.M., van Gennip A.H., Hoefnagel C.A. Diagnosis and treatment of malignant pheochromocytoma with 1311-meta-iodobenzylguanidine: a case report. Radiother. Oncol. 17: 103, 1990.

    Article  PubMed  CAS  Google Scholar 

  35. Hoefnagel C.A., Schornagel J., Valdes Olmos R.A. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J. Nucl. Biol. Med. 35: 308, 1991.

    PubMed  CAS  Google Scholar 

  36. Goncalves E., Ninane J., Wese F.X., Leonet J., Piret L., Cornu G., De Meyer R. Familial phaeochromocytoma: successful treatment with 131I-MIBG. Med. Pediatr. Oncol. 18: 126, 1990.

    Article  PubMed  CAS  Google Scholar 

  37. Theilade K., Bak M., Olsen K., Nielsen S.L., Christensen N.J. A case of malignant pheochromocytoma treated by 131 I-metaiodobenzylguanidine. Acta Oncol. 27: 296, 1988.

    Article  PubMed  CAS  Google Scholar 

  38. Sakahara H., Endo K., Saga T., Hosono M., Kobayashi H., Konishi J. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma. Ann. Nucl. Med. 8: 133, 1994.

    Article  PubMed  CAS  Google Scholar 

  39. Nakagami Y., Nomura K., Kusakabe K., Miko N., Tsushima T., Demura H. A case of malignant pheochromocytoma treated with 131I-metaiodobenzylguanidine and alpha-methyl-p-tyrosine. Jpn. J. Med. 29: 329, 1990.

    Article  PubMed  CAS  Google Scholar 

  40. Sasaki M., Iwaoka T., Yamauchi J., Tokunaga H., Naomi S., Inoue J., Oishi S., Umeda T., Sato T. A case of Sipple’s syndrome with malignant pheochromocytoma treated with 131I-metaiodobenzyl guanidine and a combined chemotherapy with cyclophosphamide, incristine and dacarbazine. Endocr. J. 41: 155, 1994.

    Article  PubMed  CAS  Google Scholar 

  41. Guo J.Z., Gong L.S., Chen S.X., Luo B.Y., Xu M.Y. Malignant pheochromocytoma: diagnosis and treatment in fifteen cases. J. Hypertens. 7: 261, 1989.

    Article  PubMed  CAS  Google Scholar 

  42. Hoefnagel C.A., Voute P.A., de Kraker J., Marcuse H.R. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J.Nucl. Med. 28: 308, 1987.

    PubMed  CAS  Google Scholar 

  43. Beierwaltes W.H. Update on basic research and clinical experience with metaiodobenzylguanidine. Med. Pediatr. Oncol. 15: 163, 1987.

    Article  PubMed  CAS  Google Scholar 

  44. Mastrangelo R., Lasorella A., Iavarone A., Rufini V., Troncone L., Danza F., Riccardi R. Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis. Med. Pediatr. Oncol, 21: 411, 1993.

    Article  PubMed  CAS  Google Scholar 

  45. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47: 207, 1981.

    Article  PubMed  CAS  Google Scholar 

  46. Hoefnagel C.A. Radionuclide therapy revisited. Eur. J. Nucl. Med. 18: 408, 1991.

    Article  PubMed  CAS  Google Scholar 

  47. Koral K.F., Wang X.H., Sisson J.C., Botti J., Meyer L., Mallette S., Glazer G.M., Adler R.S. Calculating radiation absorbed dose for pheochromocytoma tumors in 131ImIBG therapy. J. Rad. Oncol. Biol. 17: 211, 1989.

    Article  CAS  Google Scholar 

  48. Vaidyanathan G., Zalutsky M.R. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot (Int. J. Rad. Appl Instrum. [A]. 44: 621, 1993.

    CAS  Google Scholar 

  49. Mangner J.T., Wu J.-L., Wieland D.M. Solid-phase exchange radioiodination of aryl iodides: facilitation by ammonium sulfate. J.Org.Chem. 47: 1484, 1982.

    Article  CAS  Google Scholar 

  50. Mairs R.J., Cunningham S.H., Russell J., Armour A., Owens J., McKellar K., Gaze M.N. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. J. Nucl. Med. 36: 1088, 1995.

    PubMed  CAS  Google Scholar 

  51. Mairs R.J., Russell J., Cunningham S., O’Donoghue J.A., Gaze M.N., Owens J., Vaidyanathan G., Zalutsky, M.R. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I] meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Eur. J. Cancer. 31A: 576, 1995.

    Article  PubMed  CAS  Google Scholar 

  52. Sisson J.C., Hutchinson R.J., Carey J.E., Shapiro B., Johnson J.W., Mallette SA, Wieland DM. Toxicity from treatment of neuroblastoma with 131I-metaiodobenzylguanidine. Eur. J. Nucl. Med. 14: 337, 1988.

    PubMed  CAS  Google Scholar 

  53. Blake G.M., Lewington V.J., Fleming J.S., Zivanovic M.A., Ackery D.M. Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant pheochromocytoma. Eur. J. Nucl. Med. 14: 345, 1988.

    PubMed  CAS  Google Scholar 

  54. Khafagi F.A., Shapiro B., Fig L.M., Mallette S., Sisson J.C. Labetalol reduces iodine-131-MIBG uptake by pheochromocytoma and normal tissues. J.Nucl. Med. 30: 481, 1989.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology & Metabolism, Department of Medicine & Metabolic Research Unit, University of California at San Francisco, San Francisco, CA, 94143, USA

    Keh-Chuan Loh, P. A. Fitzgerald & P. P. B. Yeo

  2. Division of Hematology-Oncology, Department of Pediatrics, University of California at San Francisco, San Francisco, CA, 94143, USA

    K. K. Matthay

  3. Nuclear Medicine Program, Department of Radiology, University of California at San Francisco, San Francisco, CA, 94143, USA

    D. C. Price

  4. Department of Medicine, Tan Tock Seng Hospital, Moulmein Road, Singapore, 308433, Republic of Singapore

    Keh-Chuan Loh

Authors
  1. Keh-Chuan Loh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. A. Fitzgerald
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. K. Matthay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. P. B. Yeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. C. Price
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loh, KC., Fitzgerald, P.A., Matthay, K.K. et al. The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 20, 648–658 (1997). https://doi.org/10.1007/BF03348026

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03348026

Key-words

Search

Navigation